Table 3.
Adverse Event n (%) | Placebo (n = 22) | 260 mg ADS‐5102 (n = 20) | 340 mg ADS‐5102 (n = 21) | 420 mg ADS‐5102 (n = 20) |
---|---|---|---|---|
Constipation | 2 (9.1) | 7 (35.0) | 5 (23.8) | 3 (15.0) |
Dizziness | 1 (4.5) | 3 (15.0) | 6 (28.6) | 3 (15.0) |
Hallucination | 0 | 4 (20.0) | 5 (23.8) | 4 (20.0) |
Dry mouth | 0 | 3 (15.0) | 4 (19.0) | 2 (10.0) |
Fall | 3 (13.6) | 1 (5.0) | 3 (14.3) | 3 (15.0) |
Confusion | 1 (4.5) | 1 (5.0) | 3 (14.3) | 2 (10.0) |
Headache | 1 (4.5) | 1 (5.0) | 3 (14.3) | 1 (5.0) |
Nausea | 1 (4.5) | 1 (5.0) | 3 (14.3) | 1 (5.0) |
Asthenia | 1 (4.5) | 0 | 3 (14.3) | 1 (5.0) |